A solid-phase antibody capture assay for the measurement of Cl-inhibitor consumption in vivo

References

• Carrell RW, Boswell DR. Serpins: the superfamily of plasma serine proteinase inhibitors. Proteinase inhibitors. Research Monographs in Cell and Tissue Physiology, AJ Barrett, G Salvesen. Elsevier, Amsterdam 1986; Vol 12: 403–20
   Google Scholar
• Davis AE., III. C1-Inhibitor and hereditary angioneurotic edema. Annu Rev Immunol 1988; 6: 595–628
   PubMed Web of Science ®Google Scholar
• Heidtmann H, Travis J. Human α-1-proteinase inhibitor. Proteinase inhibitors. Research Monographs in Cell and Tissue Physiology, AJ Barrett, G Salvesen. Elsevier, Amsterdam 1986; Vol 12: 441–55
   Google Scholar
• Miura O, Hirosawa S, Kato A, Aoki N. Molecular basis for congenital deficiency of α-2-plasmin inhibitor. J Clin Invest 1989; 83: 1598–604
   PubMedGoogle Scholar
• Beresford CH, Owen MC. Antithrombin III. Int J Biochem 1990; 22(2)121–8
   PubMedGoogle Scholar
• Wiman B. Human C1 inhibitor. Proteinase inhibitors. Research Monographs in Cell and Tissue PhysiologyVol 12., AJ Barrett, G Salvesen. Elsevier, Amsterdam 1986; 477–88
   Google Scholar
• Travis J, Salvesen GS. Human plasma proteinase inhibitors. Annu Rev Biochem 1983; 52: 655–709
   PubMed Web of Science ®Google Scholar
• Bode W, Huber R. Natural proteh proteinase inhibitors and their interaction with proteinases. Eur J Bioohem 1992; 204: 433–51
   PubMedGoogle Scholar
• Harpel PC, Cooper NR. Studies on human C1 inactivator-enzyme interactions. J Clin Invest 1975; 55: 593–604
   PubMed Web of Science ®Google Scholar
• Van der Graaf F, Koedam JA, Griffin JH, Bouma BM. Interaction of human plasma kallikrein and its fight chain with C1-inhibitor. Biochemistry 1983; 22: 4860–6
   PubMedGoogle Scholar
• Weiss V, Engel J. Heparin-stimulated modification of C1-inhibitor by subcomponent Cls of human complement. Hoppe-Seyler's Z Physiol Chem 1983; 364: 295–301
   PubMedGoogle Scholar
• Nilsson T, Sjoholm I, Wiman B. Structural and circular-dichroism studies on the interaction between human C1 esterase inhibitor and Cls. Biochem J 1983; 213: 617–24
   PubMedGoogle Scholar
• Salvesen GS, Catanese JJ, Kress LF, Travis J. Primary structure of the reactive site of human C1-inhibitor. J Biol Chem 1985; 260: 2432–6
   PubMed Web of Science ®Google Scholar
• Donaldson VH, Harrison RA, Rosen FS, Bing DH, Kindness J, Canar J, Wagner CJ, Awad S. Variability in purified dysfunctional C1-inhibitor proteins from patients with hereditary angioneurotic edema. J Clin Invest 1985; 75: 124–32
   PubMed Web of Science ®Google Scholar
• Jackson J, Sim RB, Whaley K, Feighery C. Autoantibody facilitated cleavage of C1-inhibitor in autoimmune angioedema. J Clin Invest 1989; 83: 698–707
   PubMed Web of Science ®Google Scholar
• De Agostini A, Patson PA, Marottoli V, Carrel S, Harpel PC, Schapira M. A common neoepitope is created when the reactive centre of C1-inhibitor is cleaved by plasma kallikrein, activated factor XIIa, C1 esterase, or neutrophil elastase. J Clin Invest 1988; 82: 700–5
   PubMedGoogle Scholar
• Patson PA, Gettins P, Beecham J, Schapira M. Mechanism of serpin action: evidence that C1 inhibitor functions as a suicide substrate. Biochemistry 1991; 30: 8876–82
   PubMedGoogle Scholar
• Zuraw BL, Curd JG. Demonstration of modified inactive first component of complement (C1) inhibitor in the plasmas of C1 inhibitor-deficient patients. J Clin Invest 1986; 78: 567–75
   PubMed Web of Science ®Google Scholar
• Wachtfogel YT, Harpel PC, Edmunds LH, Jr., Coleman RW. Formation of Cls-C1-inhibitor, kallikrein-C1-inhibitor and plasmin-α-2-plasmin inhibitor complexes during cardiopulmonary bypass. Blood 1988; 73(2)468–71
   Google Scholar
• Nuijens JH, Eerenberg-Belmer JM, Huijbregts CCM, Schreuder WO, Felt-Bersma RJF, Abbink JJ, Thijs LG, Hack CE. Proteolytic inactivation of plasma C1 inhibitor in sepsis. J Clin Invest 1989; 84: 443–50
   PubMed Web of Science ®Google Scholar
• Cugno M, Nuijens J, Hack CE, Eerenber A, Frangi D, Agostini A, Cicardi M. Plasma levels of C1 inhibitor complexes and cleaved C1 inhibitor in patients with hereditary angioneurotic edema. J Clin Invest 1990; 85: 1215–20
   PubMed Web of Science ®Google Scholar
• Harpel PC, Cooper NR. Circulating C1-inactivator-Cls-Clr complexes: quantification by an enzyme-linked differential antibody immunosorbent assay. Clin Res 1982; 30: 566A
   Google Scholar
• Lewin MF, Kaplan AP, Harpel PC. Studies of C1 inactivator-plasma kallikrein complexes in purified systems and in plasma. Quantification by an enzyme-linked differential antibody immunosorbent assay. J Biol Chem 1983; 258(10)6415–21
   PubMedGoogle Scholar
• Nilsson T, Back O. Determination of Cls-Cl inhibitor complexes in plasma by means of an enzyme-linked immunosorbent assay. Clin Exp Immunol 1985; 60: 178–82
   PubMedGoogle Scholar
• Langlois PF, Gawryl MS. Complement activation occurs through both classical and alternative pathways prior to onset and resolution of adult respiratory distress syndrome. Clin Immunol Immunopathol 1988; 47(2)152–63
   PubMedGoogle Scholar
• Laurell AB, Martensson U, Sjoholm AG. Trimer and tetramer complexes containing C1 esterase inhibitor, Clr and Cls, in serum and synovial fluid of patients with rheumatic disease. J Immunol Methods 1990; 129: 55–61
   PubMedGoogle Scholar
• Abbink JJ, Kamp AM, Swaak AJG, Hack CE. Production of monoclonal antibodies against inactivated α-1-antitrypsin. Cross reactivity with complexed α-1-antitrypsin and application in an assay to determine inactivated and complexed α-l-anti-trypsin in biological fluids. J Immunol Methods 1991; 143: 197–208
   PubMedGoogle Scholar
• Dolman KM, van de Wiel BA, Kamp CM, Abbink JJ, Hack CE, Somenberg A, et al. Determination of proteinase 3–α-1-antitrypsin complexes in inilammatory fluids. FEBS Lett 1992; 314(2)117–121
   PubMedGoogle Scholar
• Kummer JA, Abbink JJ, de Boer JP, Roem D, Niewenhuys EJ, Kamp AM, et al. Analysis of intraarticular fibrinolytic pathways in patients with idammatory and non-inflammatory joint disease. Arthritis Rheumat 1992; 35(8)884–93
   PubMedGoogle Scholar
• Laemmli UK. Cleavage of structural proteins during the assembly of the head of the bacteriophage T4. Nature (London) 1970; 227: 680–6
   PubMed Web of Science ®Google Scholar
• Hack CE, Hannema AJ, Ebrenberg-Behmer AJ, Gut AT, Alberse RG. C1 inhibitor complex assay (INCA): a method to detect C1 activationin vitroand in viva. J Immunol Methods 1981; 127: 1450–3
   Google Scholar
• Nuijens JH, Huijbregts CCM, Eerenberg-Belmer AJM, Abbink JJ, Strack van Schijndel RJM, Felt-Bersam RJF, et al. Quantification of plasma factor XIIa-C1 -inhibitor and kallikrein-C1 -inhibitor complexes in sepsis. Blood 1988; 72(6)1841–8
   PubMedGoogle Scholar
• Skriver K, Witkoff WR, Patson PA, Tausk F, Schapira M, Bock SC. Substrate properties of C1 inhibitor Ma (Alanine 434-Glutamic acid). J Biol Chem 1991; 266: 9216–21
   PubMed Web of Science ®Google Scholar
• Perlmutter DH, Glover GI, Rivetna M, Schasteen CS, Fallon RJ. Identification of a serpin-enzyme complex receptor on human hepatoma cells and human monocytes. Proc Natl Acad Sci USA 1990; 87: 3753–7
   PubMed Web of Science ®Google Scholar
• Chesne S, Villiers CL, Arlaud GJ, Lacroix MB, Colomb MG. Fluid phase interaction of C1-inhibitor (C1-Inh) and the subcomponents Clr and Cls of the fmt component of complement, C1. Biochem J 1982; 201: 61–70
   PubMed Web of Science ®Google Scholar